Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma (NHL),
comprising about 6% .... It is showing better complete remissions (CR) and
progression free survival (PFS) than CHOP regimen...
Mantle cell lymphoma (MCL) is a rare, B-cell NHL that most often affects men
over ... and monitoring the disease for progression may be an acceptable option.
Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin's ....
The progression-free survival (PFS) at 6 years was 70%, similar to results with ...
The 6-year overall, event-free, and progression-free survival were 70%, 56%,
and 66%, ... Mantle cell lymphoma (MCL) is considered incurable, with a reported
Mantle-cell lymphoma (MCL) is known to have a poor outcome, however, most
patients .... Progression-free survival for 26 patients with limited-stage mantle-cell
Jul 15, 2009 ... Mantle cell lymphoma (MCL) is a distinct subtype of non-Hodgkin ... Progress has
been made in MCL therapy in the past decade based on ...
May 17, 2016 ... Peter Martin, M.D. Patients with mantle cell lymphoma who progressed on
ibrutinib have poor outcomes and no effective therapies following ...
Feb 1, 2009 ... Recognition of mantle-cell lymphoma (MCL) in the 1994 Revised European-
American Lymphoma classification of lymphoid neoplasms as a ...
Jan 25, 2016 ... Ibrutinib is a marvelous addition to mantle cell lymphoma treatment ... time to
progression of 6 months, and median duration of response of 9 ...
Mar 2, 2015 ... Outcome of patients with mantle cell lymphoma who experience disease
progression following ibrutinib therapy is poor.